Olverembatinib for cancers with FGFR1 gene changes
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial studies olverembatinib to treat certain blood cancers that have an FGFR1 rearrangement (a specific gene change). It’s for people whose disease is newly diagnosed, has progressed, or has come back, and who can safely take the study medicine and attend follow-up visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a myeloid or lymphoid blood cancer with an FGFR1 rearrangement
- You have not had an allogeneic stem cell transplant, and you have not taken ponatinib
- Your overall health score (ECOG) is within the trial limits (MPNs: 0–3; AL: 0–2)
- You are expected to live at least 12 weeks
- You can follow study visits and procedures, including follow-up exams
- You are not pregnant, trying to become pregnant, or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a drug called olverembatinib is processed by the body in people with different levels of liver impairment. It looks at how the liver condition affects the drug levels and safety, which may help find the right dose.
This trial tests two medicines together: olverembatinib (a pill) and blinatumomab (given by infusion). It is for people who are newly diagnosed with Ph+ ALL and have not had chemotherapy yet. The goal is to see if this combination works well and is safe.
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
This study tests a new targeted drug called olverembatinib for people with chronic myeloid leukemia (CML) that has stopped responding to other treatments. It aims to see if the drug can control the leukemia with fewer side effects.
This trial tests the drug olverembatinib alone for people with newly diagnosed chronic phase CML who have not had much prior treatment. It aims to see how well the drug works and what side effects it may cause.
This study looks at whether lowering the dose of olverembatinib (from 30 or 40 mg to 20 mg every other day) keeps working well for people with chronic myeloid leukemia who have already had a good response. It aims to see if a lower dose can still control the cancer while possibly reducing side effects.
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.